An analysis of the Nationwide Readmission Database revealed one-fifth of transcatheter aortic valve replacement patients are readmitted a median of 31 days after discharge. Medical comorbidities are the most common reason.
A 12-year experience with transcatheter aortic valve replacement at one Paris hospital demonstrated chronic systemic corticosteroid use increases the incidence of major 30-day complications and all-cause mortality at one year.
A study of all patients who underwent transcatheter aortic valve replacement over eight years in France was used to develop a futility score that would help predict who would not live one year after the procedure. This simple clinical score based on comorbidities predicted who would live one year with 95% specificity.
Investigators assessed the Society of Thoracic Surgeons/American College of Cardiology transcatheter aortic valve replacement (TAVR) data, with a focus on the use of newer TAVR devices in patients with bicuspid aortic valve vs. tricuspid aortic valves. They found the outcomes post-procedure and for one year are not significantly different between the two types of native valve anatomy.
In a randomized trial of patients already on anticoagulation undergoing transcatheter aortic valve replacement, adding clopidogrel to oral anticoagulation increased the incidence of serious bleeding vs. oral anticoagulation alone, but did not improve cardiovascular outcomes.